"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
| Descriptor ID |
D014740
|
| MeSH Number(s) |
D03.633.100.759.590.138.900 D13.570.065.950 D13.570.583.138.900
|
| Concept/Terms |
Vidarabine- Vidarabine
- beta-Ara A
- beta Ara A
- Adenine Arabinoside
- Arabinoside, Adenine
- alpha-D-Arabinofuranosyladenine
- alpha D Arabinofuranosyladenine
- Ara A
- alpha-Ara A
- alpha Ara A
- Arabinofuranosyladenine
- Arabinosyladenine
- 9-beta-D-Arabinofuranosyladenine
- 9 beta D Arabinofuranosyladenine
- 9-beta-Arabinofuranosyladenine
- 9 beta Arabinofuranosyladenine
- Ara-A
|
Below are MeSH descriptors whose meaning is more general than "Vidarabine".
Below are MeSH descriptors whose meaning is more specific than "Vidarabine".
This graph shows the total number of publications written about "Vidarabine" by people in this website by year, and whether "Vidarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vidarabine" by people in Profiles.
-
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1460-70.
-
Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link? Anticancer Res. 2005 Jan-Feb; 25(1B):429-33.